![Lior Shaltiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lior Shaltiel
Chief Executive Officer at
NUREXONE BIOLOGIC INC.
Net worth: 628 425 $ as of 30/08/2026
Profile
Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 26/11/2025 | 1,575,000 ( 1.67% ) | 628 425 $ | 30/08/2026 |
Lior Shaltiel active positions
| Companies | Position | Start |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Chief Executive Officer | 31/03/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Chief Executive Officer | 31/03/2021 |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 30/09/2015 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
71
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
NurExone Biologic, Inc.
 NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
- Stock Market
- Insiders
- Lior Shaltiel
